ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TRML Tourmaline Bio Inc

13.56
-0.35 (-2.52%)
Jun 06 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 111,257
Bid Price 12.55
Ask Price 13.99
News -
Day High 14.12

Low
9.18

52 Week Range

High
48.31

Day Low 13.38
Company Name Stock Ticker Symbol Market Type
Tourmaline Bio Inc TRML NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.35 -2.52% 13.56 20:00:00
Open Price Low Price High Price Close Price Prev Close
13.91 13.38 14.12 13.56 13.91
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,615 111,257 $ 13.68 $ 1,521,847 - 9.18 - 48.31
Last Trade Time Type Quantity Stock Price Currency
19:47:22 4 $ 13.80 USD

Tourmaline Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
275.97M 20.34M - 0 -42.12M -2.07 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tourmaline Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TRML Message Board. Create One! See More Posts on TRML Message Board See More Message Board Posts

Historical TRML Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.6014.5412.9813.68349,226-0.04-0.29%
1 Month15.5515.9612.9814.09272,646-1.99-12.80%
3 Months45.2646.3612.9820.97462,987-31.70-70.04%
6 Months19.3448.3112.9825.31334,296-5.78-29.89%
1 Year10.3248.319.1824.82279,9903.2431.40%
3 Years10.3248.319.1824.82279,9903.2431.40%
5 Years10.3248.319.1824.82279,9903.2431.40%

Tourmaline Bio Description

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.